Incyte (INCY)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$118.05+2.10%
Close 2026-07-07 · 1-day change
Reading INCY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track INCY free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading INCY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track INCY free→QuarterlyIQ Insights · INCY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On July 6, 2026, Incyte Corporation (the “Company”) issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC (“Vega Therapeutics”). A copy of the Company’s press release announcing the completion of its acquisition of Vega Therapeutics is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Other Events. Incyte Corporation (the “Company”) today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura ® (ruxolitinib) cream. Under the agreement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi ® (ruxolitinib), and the Company has withdrawn its lawsuit challenging the regulations. The set…
Results of Operations and Financial Condition. On April 28, 2026 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1.
Director — Susanne Schaffert: Dr. Susanne Schaffert resigned from the Board of Directors effective April 15, 2026.
President, Incyte and Global Head of Research and Development — Pablo J. Cagnoni: Title changes for certain current members of the executive leadership team, including an internal promotion.
Other Events. On February 27, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for the supplemental Biologics License Application (“sBLA”) for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer (“NSCLC”) in combination with platinum-based chemotherapy. The sBLA was supported by positive efficacy and safety data from the Phase 3 POD1UM-304 trial ann…
Results of Operations and Financial Condition. On February 10, 2026, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1.
Director — Hervé Hoppenot: Hervé Hoppenot retired from the Board of Directors.
Results of Operations and Financial Condition. On October 28, 2025 , Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1.
principal financial officer — Thomas Tray: Mr. Tray was promoted to the additional position of principal financial officer.
Chief Financial Officer — Christiana Stamoulis: Ms. Stamoulis is leaving to pursue another opportunity.
Results of Operations and Financial Condition. On July 29, 2025 , Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1.
President and Chief Executive Officer — Hervé Hoppenot: Hervé Hoppenot retired as President and Chief Executive Officer, with a transition agreement in place.
The filing pertains to amendments in stock incentive and employee stock purchase plans.
Other Events On May 11, 2025, Incyte Corporation (the “Company”) and Novartis Pharma AG (“Novartis”) entered into a settlement agreement (the “Settlement Agreement”) with respect to litigation initiated by Novartis and relating to the duration of royalty payments owed by the Company to Novartis under the Collaboration and License Agreement dated November 24, 2009, as amended, between the Company and Novartis. As of March 31, 2025, the Company had approximately $537.1 million of accrued royalt…
Results of Operations and Financial Condition. On April 29, 2025 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1.
Results of Operations and Financial Condition. On February 10, 2025, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1.
Executive Vice President, General Manager, North America — Barry P. Flannelly: Dr. Flannelly retired and stepped down from his role, but a successor has been named.
Results of Operations and Financial Condition. On October 29, 2024 , Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2024. The full text of the press release is furnished as Exhibit 99.1.
Results of Operations and Financial Condition. On July 30, 2024 , Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Entry Into a Material Definitive Agreement . On June 28, 2024, Incyte Corporation (the “Company”) and its subsidiary, Incyte Holdings Corporation (“Incyte Holdings”), entered into Amendment No. 2 (“Amendment No. 2”) to the Revolving Credit and Guaranty Agreement dated as of August 21, 2021 among the Company, as borrower, Incyte Holdings, as a guarantor, the lenders from time to time party thereto, J.P. Morgan Chase Bank, N.A. as administrative agent, and the other financial institutions party…
Entry Into a Material Definitive Agreement . On May 12, 2024, Incyte Corporation (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with Julian C. Baker, a member of the Company’s board of directors, Felix J. Baker, and entities affiliated with Julian C. and Felix J. Baker, including funds advised by Baker Bros. Advisors LP (collectively, the “Baker Entities”). The Baker Entities, in the aggregate, own 36,833,933 shares of the Company’s common stock, representi…
Results of Operations and Financial Condition. On April 30, 2024 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2024. The full text of the press release is furnished as Exhibit 99.1.
Results of Operations and Financial Condition. On February 13, 2024, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.